Clinical trials: Severe Mental Illness
Major Depressive Disorder, Suicide
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Approximately four thousand Canadians die by suicide every year, and suicide is the second leading cause of death in youth and young adults (15-34 years).
- Conditions
- Major Depressive Disorder, Suicide, Treatment Resistant Depression
- Trial name
- Ket-CBT (NCT06480500)
- Testing
- Ketamine hydrochloride, i-CBT (Internet-based Cognitive Behavioural Therapy), Midazolam Hydrochloride
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- University Health Network, Toronto
Major Depression, Major Depression Disorders
Accelerated High-Dose tDCS for Depression
In this study, investigators are testing whether a higher dose of a non-invasive brain stimulation technique, called transcranial direct current stimulation (tDCS), can be safely used in people with depression.
- Trial name
- NCT07226011
- Testing
- Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical University of South Carolina
Major Depressive Disorder, Bipolar Disorder
Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy (fNIRS) Study
The purpose of this research is to measure brain activity in individuals with mood disorders and memory problems using a simple, safe, and noninvasive method called functional near-infrared spectroscopy (fNIRS).
- Conditions
- Major Depressive Disorder, Bipolar Disorder, Mild Cognitive Impairment
- Trial name
- NCT06897670
- Testing
- Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels.
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Mayo Clinic
Major Depressive Disorder, Post-Traumatic Stress Disorder
Imaging SV2A in Mood Disorders
This study is designed to examine SV2A density in MDD and PTSD as a correlate of synaptic density, and to determine whether ketamine administration will reverse the synaptic loss in vivo in human subjects.
- Trial name
- NCT02734602
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Yale University
Substance Withdrawal Syndrome, Opiate Addiction
Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction
The purpose of this study is to evaluate the relative exposures of lofexidine and its major metabolites in subjects seeking buprenorphine dose reduction.
- Conditions
- Substance Withdrawal Syndrome, Opiate Addiction, Opiate Dependence
- Trial name
- NCT02801357
- Testing
- lofexidine administration in subjects seeking buprenorphine dose reduction
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Major Depressive Disorder
Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients
Our hypothesis is that using antidepressants during the ECT has a better efficacy and longer time to relapse/recurrence to the ECT without antidepressants.
- Trial name
- NCT04181567
- Testing
- electroconvulsive therapy, agomelatine
- Where
- Taiwan
- Volunteers
- 97 people
- Sponsor
- Kaohsiung Kai-Suan Psychiatric Hospital
Healthy Volunteers, Moderate to Severe Alzheimer Patients
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
This is a dual-centre, Phase I/IIa study, in healthy subjects and subjects with AD to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201.
- Trial name
- NCT01513967
- Testing
- RPh201, botanical drug product
- Where
- 2 sites in Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Regenera Pharma Ltd
Schizophrenia, Schizoaffective Disorder
Evaluation of mHealth for Serious Mental Illness
This study is a waitlist control trial evaluating the acceptability and preliminary efficacy of a smartphone application with people with mental illness.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depressive Disorder, Bipolar Disorder
- Trial name
- NCT04068467
- Testing
- Smartphone App, Waitlist Control
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- University of Washington
Anodal Stimulation tDCS, Major Depression
Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients
Deficient cognitive control (CC) and the use of dysfunctional emotion regulation strategies (ERS) are both central characteristics of major depression.
- Conditions
- Anodal Stimulation tDCS, Major Depression, Cognitive Control, Emotion Regulation
- Trial name
- NCT03039387
- Testing
- anodal transcranial direct current stimulation
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Schizophrenia Disorders, Major Depression
Non-Coding RNAs Gene Expression in Psychiatric Disorders
This study aims to investigate whether specific non-coding RNAs, molecules involved in the regulation of gene expression, are altered in individuals with psychiatric disorders such as schizophrenia, bipolar disorder, major…
- Conditions
- Schizophrenia Disorders, Major Depression, Bipolar Affective Disorders, Obsessive Compulsive Disorder (OCD)
- Trial name
- PsiRNA26 (NCT07649993)
- Testing
- Reverse Transcription Quantitative Polymerase Chain Reaction
- Where
- 5 sites in Italy
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Carmen Concerto
Multiple Sclerosis, Major Depressive Disorder
Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis
The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS.
- Conditions
- Multiple Sclerosis, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT06329414
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Major Depressive Disorder
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment…
- Trial name
- JUNIPER (NCT05536414)
- Testing
- Centanafadine, Escitalopram
- Where
- 62 sites in United States
- Volunteers
- 337 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder, Treatment Resistant Depression
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Over 28 million people suffer from current depressive disorder in the European Union. Major depressive disorder (MDD) is one of the most common psychiatric illnesses.
- Trial name
- INTENSIFY MDD (NCT05973851)
- Testing
- Esketamine Nasal Product, Ketamine Hydrochloride, Esketamine hydrochloride
- Where
- 12 sites in Austria, Germany and 4 more
- Volunteers
- 418 people
- Sponsor
- Dr. Inge Winter
Major Depressive Disorder
Optimize and Predict Antidepressant Efficacy for Patient With MDD Using Multi-omics Analysis and AI-predictive Tool
OPADE is a non-profit, observational, multicenter, open-label study aimed at defining personalized treatment for Major Depressive Disorder (MDD).
- Trial name
- OPADE (NCT06550037)
- Where
- Italy
- Volunteers
- 350 people
- Sponsor
- Alessio Fasano
Posttraumatic Stress Disorder
Imaging Outcomes of Cognitive Behavioral Therapy (CBT) for Battered Women With Posttraumatic Stress Disorder
Identifying neural mechanisms of posttraumatic stress disorder (PTSD) treatment could help elucidate reasons for variable treatment response and identify novel treatment targets.
- Trial name
- NCT01517672
- Testing
- Cognitive Trauma Therapy for Battered Women (CTT-BW)
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Major Depressive Disorder
Mobile Screening for Major Depressive Disorder in Adults From an Ethnically and Socioeconomically Diverse Population.
Major depressive disorder (MDD) is a mental disorder leading to a variety of emotional and physical problems affecting almost 300 million people worldwide.
- Trial name
- MOOD (NCT05989412)
- Testing
- Patient health questionnaire-9 via the Your Research application
- Where
- Netherlands
- Volunteers
- 1,786 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Depressive Symptoms, Major Depressive Disorder
Digital Therapeutic for Adolescent Depressive Symptoms in Cardiology and Gastroenterology
The primary aim of this pilot study is to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for symptoms of…
- Conditions
- Depressive Symptoms, Major Depressive Disorder, Depression, Cardiology
- Trial name
- NCT05461599
- Testing
- SparkRx Mobile App
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Limbix Health, Inc.
Dementia with Behavioral Disturbance
MEDical CANnabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva
The behavioral and psychological symptoms of dementia affect up to 80% of long-term facilities residents with severe dementia. They seriously alter the quality of life of patients, relatives, and health professionals.
- Trial name
- MedCanDem (NCT05432206)
- Testing
- Cannabis Sativa Oil
- Where
- Switzerland
- Volunteers
- 27 people
- Sponsor
- Fondation pour l'accueil et l'hébérement des personnes âgées
Substance Use, Severe Mental Disorder
Validation of the Dutch Translation of the Tobacco, Alcohol, Prescription Medication and Other Substances (TAPS)-Tool
The aim of the study is to investigate the reliability and validity of the Dutch version of the TAPS-tool. This will be investigated in 2 groups: patients without intellectual disabilities treated in Flexible Assertive Community…
- Conditions
- Substance Use, Severe Mental Disorder, Intellectual Disability, Mild
- Trial name
- NCT05273021
- Testing
- TAPS
- Where
- 3 sites in Netherlands
- Volunteers
- 150 people
- Sponsor
- Birgit Seelen-de Lang
Dementia
Deprescribing Intervention Among Nursing Home Residents With Major Neurocognitive Disorders
Canadians with neurocognitive disorders often are admitted to nursing homes when their disease reaches an advanced stage. At the end of their life, they may encounter adverse symptoms related to medications they no longer need…
- Trial name
- OptimaMedLTC (NCT05155748)
- Testing
- Continuous education and knowledge exchange
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Dre Edeltraut Kröger
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.